Results 41 to 50 of about 319,103 (346)

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

open access: yesCancers, 2022
Simple Summary The estimated survival time for glioblastoma patients is extremely low; only about 5% of patients survive five years post diagnosis. The standard of care for glioblastoma patients involves surgery, radiation therapy, and chemotherapy with ...
Fidan Seker-Polat   +3 more
semanticscholar   +1 more source

The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ‐dependent inhibition of the AKT pathway

open access: yesEMBO Molecular Medicine, 2016
A variety of drugs targeting monoamine receptors are routinely used in human pharmacology. We assessed the effect of these drugs on the viability of tumor‐initiating cells isolated from patients with glioblastoma.
Suzana Assad Kahn   +18 more
doaj   +1 more source

Regulatory pattern of abnormal promoter CpG island methylation in the glioblastoma multiforme classification

open access: yesFrontiers in Genetics, 2022
Glioblastoma (GBM) is characterized by extensive genetic and phenotypic heterogeneity. However, it remains unexplored primarily how CpG island methylation abnormalities in promoter mediate glioblastoma typing.
Rendong Wang   +10 more
doaj   +1 more source

Research Progress of Diagnosis and Treatment of Glioblastoma

open access: yesZhongliu Fangzhi Yanjiu, 2022
Glioblastoma is the most common primary malignant brain tumor. Despite large-scale researches have been carried out, the prognosis of glioblastoma is still not significantly improved.
CHEN Qianxue
doaj   +1 more source

An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment

open access: yesCancer Communications, 2022
Glioblastoma multiforme (GBM) is the most aggressive and common malignant primary brain tumor. Patients with GBM often have poor prognoses, with a median survival of ∼15 months.
Elena Verdugo, Iker Puerto, M. Medina
semanticscholar   +1 more source

The Glioblastoma CircularRNAome

open access: yesInternational Journal of Molecular Sciences, 2023
Glioblastoma remains one of the most aggressive cancers of the brain, warranting new methods for early diagnosis and more efficient treatment options. Circular RNAs (circRNAs) are rather new entities with increased stability compared to their linear counterparts that interact with proteins and act as microRNA sponges, among other functions.
Alexandru Tirpe   +8 more
openaire   +2 more sources

Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.

open access: yesNeuro-Oncology, 2020
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but ...
P. Wen   +39 more
semanticscholar   +1 more source

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

open access: yesFrontiers in Immunology, 2022
Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades.
Paris M. Kollis   +20 more
doaj   +1 more source

Angiogenesis in Glioblastoma [PDF]

open access: yesNew England Journal of Medicine, 2013
Recent work suggests that glioblastoma cells can differentiate into endothelial cells and pericytes, thus providing a means of tumor vascularization.
Philip A. Marsden, Sunit Das
openaire   +3 more sources

Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy

open access: yesNature Communications, 2020
Cancer stem cells are critical for cancer initiation, development, and treatment resistance. Our understanding of these processes, and how they relate to glioblastoma heterogeneity, is limited.
C. Couturier   +20 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy